Key Points – McKesson raised its fiscal 2027 outlook after a stronger-than-expected first quarter, with revenue up 8% to $105.4 billion and adjusted EPS up 20% to $9.93.
The company now expects adjusted EPS of $44.20 to $45.00 for the full year. – North American Pharmaceutical led results, while GLP-1 distribution revenue surged 24% year over year to $15 billion
Oncology & Multispecialty and Prescription Technology Solutions also delivered double-digit operating-profit growth. – McKesson advanced the planned separation of its Medical-Surgical Solutions business under the Wellverse brand, while returning $2.6 billion to shareholders through buybacks and dividends and raising its quarterly dividend 15%. – 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles McKesson (NYSE:MCK) reported fiscal first-quarter 2027 results that exceeded its expectations, citing broad-based momentum across its operating businesses and prompting the healthcare services company to raise its full-year adjusted earnings outlook. Revenue rose 8% to $105.4 billion, while adjusted diluted earnings per share increased 20% to $9.93. Chair and CEO Brian Tyler said three reporting segments posted double-digit operating-profit growth, supported by stable utilization, volume growth and the company’s portfolio of healthcare distribution, specialty and technology services. – MarketBeat Week in Review – 07/27- 07/31 “Our first quarter performance reflects the continued momentum across the enterprise and reinforces our confidence in our strategy and the durability of our operating model,” Tyler said.
Guidance raised as North American Pharmaceutical leads growth McKesson raised its fiscal 2027 adjusted EPS outlook to a range of $44.20 to $45.00, from prior guidance of $43.80 to $44.60. The revised outlook implies adjusted EPS growth of 13% to 15%, excluding the impact of the Norway divestiture and a fiscal 2026 gain tied to the sale of an equity investment within The US Oncology…